Abbott Laboratories Inc. has agreed to pay $5.47 million to the U.S. government to settle kickback allegations tied to its carotid, biliary and peripheral vascular products.
The deal resolves a federal investigation into charges that Abbott violated the Anti-Kickback Statute and the False Claims Act by knowingly paying physicians for teaching assignments, speaking engagements and conferences...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?